DDInter1836 DDInter1376
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Torasemide {u} (Compound) treats {v} (Disease) hypertension
Torasemide {u} (Compound) binds {v} (Gene) CYP2C9
Torasemide {u} (Compound) upregulates {v} (Gene) PAK1
Torasemide {u} (Compound) palliates {v} (Disease) chronic kidney failure
Torasemide {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis at Loop of Henle
Torasemide {u} (Compound) downregulates {v} (Gene) ADI1
Torasemide {u} (Compound) causes {v} (Side Effect) Oropharyngeal discomfort
Torasemide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Oxytetracycline
Torasemide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Torasemide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin lispro
Torasemide (Compound) treats hypertension (Disease)
Torasemide (Compound) binds CYP2C9 (Gene)
Torasemide (Compound) upregulates PAK1 (Gene)
Torasemide (Compound) palliates chronic kidney failure (Disease)
Torasemide (Compound) is included by Increased Diuresis at Loop of Henle (Pharmacologic Class)
Torasemide (Compound) downregulates ADI1 (Gene)
Torasemide (Compound) causes Oropharyngeal discomfort (Side Effect)
Torasemide may cause a minor interaction that can limit clinical effects when taken with Oxytetracycline
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro